MENU
+Compare
EXEL
Stock ticker: NASDAQ
AS OF
Dec 26, 10:32 AM (EDT)
Price
$33.80
Change
-$0.01 (-0.03%)
Capitalization
9.66B

EXEL Exelixis Forecast, Technical & Fundamental Analysis

a developer of small molecule therapies for the treatment of cancer

Industry Biotechnology
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for EXEL with price predictions
Dec 24, 2024

EXEL in upward trend: price rose above 50-day moving average on December 23, 2024

EXEL moved above its 50-day moving average on December 23, 2024 date and that indicates a change from a downward trend to an upward trend. In of 47 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EXEL advanced for three days, in of 309 cases, the price rose further within the following month. The odds of a continued upward trend are .

EXEL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 281 cases where EXEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for EXEL moved out of overbought territory on December 02, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on December 17, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on EXEL as a result. In of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXEL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EXEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.244) is normal, around the industry mean (18.292). P/E Ratio (21.819) is within average values for comparable stocks, (87.498). Projected Growth (PEG Ratio) (2.618) is also within normal values, averaging (1.756). EXEL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (4.890) is also within normal values, averaging (260.038).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

EXEL is expected to report earnings to fall 17.09% to 38 cents per share on February 11

Exelixis EXEL Stock Earnings Reports
Q4'24
Est.
$0.39
Q3'24
Beat
by $0.13
Q2'24
Beat
by $0.53
Q1'24
Missed
by $0.06
Q4'23
Beat
by $0.10
The last earnings report on October 29 showed earnings per share of 46 cents, beating the estimate of 34 cents. With 7.19K shares outstanding, the current market capitalization sits at 9.66B.
A.I. Advisor
published General Information

General Information

a developer of small molecule therapies for the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
1851 Harbor Bay Parkway
Phone
+1 650 837-7000
Employees
1310
Web
https://www.exelixis.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TSL21.471.78
+9.04%
GraniteShares 1.25x Long Tsla Daily ETF
JPEF68.640.70
+1.03%
JPMorgan Equity Focus ETF
DGRO62.150.52
+0.84%
iShares Core Dividend Growth ETF
SEIX23.88-0.02
-0.06%
Virtus Seix Senior Loan ETF
FAZ6.10-0.21
-3.33%
Direxion Daily Financial Bear 3X ETF

EXEL and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with SRPT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then SRPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+1.02%
SRPT - EXEL
36%
Loosely correlated
+1.03%
ALNY - EXEL
34%
Loosely correlated
+0.41%
TECH - EXEL
33%
Poorly correlated
+0.40%
MRSN - EXEL
32%
Poorly correlated
+5.88%
ORMP - EXEL
32%
Poorly correlated
N/A
More